Midatech Pharma Plc (MTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Midatech Pharma Plc (MTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH2347639D
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercialize oncology and other therapeutic products. The company's products include gelclair, oravig, soltamox, zuplenz, ferralet 90 and aquoral. It conducts research and development programs in areas of oncology, autoimmune diseases, pipeline, Q-octreotide, opsisporin, HCC, glioblastoma and diabetes vaccine. Midatech's products are used in treatment of diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions. The company operates through its nanoparticle manufacturing facility in Bilbao, and research facility in Cardiff. Midatech is headquartered in Abingdon, the UK.

Midatech Pharma Plc (MTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Midatech Pharma Plc, Medical Devices Deals, 2011 to YTD 2017 10

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 13

Venture Financing 14

Q Chip Raises USD3 Million Venture Financing 14

Partnerships 15

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 15

Midatech Pharma Enters into Agreement with Ophthotech 16

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 17

DARA BioSciences Enters into Commercialization Agreement with Onxeo 18

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 19

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 20

Midatech Enters Into Joint Venture With MonoSol Rx 21

Q Chip Enters Into Co-Development Agreement With International Specialty Pharma 22

Licensing Agreements 23

Midatech Pharma Enters Into Licensing Agreement with Novartis 23

Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 24

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 25

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 26

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 27

Equity Offering 28

Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 28

Midatech Pharma Raises USD50 Million in IPO 29

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 31

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD32.5 Million 32

Dara BioSciences Announces Private Placement Of Shares For USD6 Million 33

Dara BioSciences Completes Private Placement Of Shares For USD2.6 Million 34

Dara BioSciences Announces Public Offering Of Common Stock For USD2.7 Million 35

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD2.6 Million 36

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD0.3 Million 37

DARA BioSciences Completes Public Offering Of Units For USD10 Million 38

DARA BioSciences Completes Private Placement Of Preferred Stock For USD1.7 Million 40

Acquisition 42

Midatech Pharma Acquires Dara BioSciences 42

Midatech Pharma Acquires Q Chip 44

DARA BioSciences Acquires Oncogenerix 45

Midatech Pharma Plc-Key Competitors 46

Midatech Pharma Plc-Key Employees 47

Midatech Pharma Plc-Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Joint Venture 49

Recent Developments 50

Financial Announcements 50

Apr 04, 2017: Midatech Pharma Announces Audited financial results for the year ended 31 December 2016 50

Jan 20, 2017: Midatech Pharma Provides Trading Update 51

Sep 02, 2016: Midatech Pharma: Interim results for the six months ended 30 June 2016 52

Apr 13, 2016: Midatech Pharma Announces Audited financial results for the year ended 31 December 2015 53

Apr 13, 2016: Midatech Pharma Audited financial results for the year ended 31 December 2015 54

Government and Public Interest 60

Jul 07, 2016: Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy 60

Jul 07, 2016: Midatech Pharma: Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy 61

Product News 62

11/15/2016: Midatech selects MTR104 candidate for treatment of liver cancer 62

May 22, 2017: Midatech announces progress update on brain cancer therapies 63

Clinical Trials 64

Jul 26, 2017: Midatech Pharma: Completion of pre-clinical liver cancer programme 64

Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide 65

Apr 21, 2016: Midatech achieves positive dosing data for OpsiSporin Uveitis programme 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67

List of Figures

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Midatech Pharma Plc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Midatech Pharma Plc, Deals By Therapy Area, 2011 to YTD 2017 9

Midatech Pharma Plc, Medical Devices Deals, 2011 to YTD 2017 10

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 13

Q Chip Raises USD3 Million Venture Financing 14

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 15

Midatech Pharma Enters into Agreement with Ophthotech 16

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 17

DARA BioSciences Enters into Commercialization Agreement with Onxeo 18

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 19

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 20

Midatech Enters Into Joint Venture With MonoSol Rx 21

Q Chip Enters Into Co-Development Agreement With International Specialty Pharma 22

Midatech Pharma Enters Into Licensing Agreement with Novartis 23

Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 24

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 25

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 26

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 27

Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 28

Midatech Pharma Raises USD50 Million in IPO 29

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 31

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD32.5 Million 32

Dara BioSciences Announces Private Placement Of Shares For USD6 Million 33

Dara BioSciences Completes Private Placement Of Shares For USD2.6 Million 34

Dara BioSciences Announces Public Offering Of Common Stock For USD2.7 Million 35

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD2.6 Million 36

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD0.3 Million 37

DARA BioSciences Completes Public Offering Of Units For USD10 Million 38

DARA BioSciences Completes Private Placement Of Preferred Stock For USD1.7 Million 40

Midatech Pharma Acquires Dara BioSciences 42

Midatech Pharma Acquires Q Chip 44

DARA BioSciences Acquires Oncogenerix 45

Midatech Pharma Plc, Key Competitors 46

Midatech Pharma Plc, Key Employees 47

Midatech Pharma Plc, Subsidiaries 48

Midatech Pharma Plc, Joint Venture 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Midatech Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com